

Overview

The WHO recommends that **trivalent** vaccines for use in the 2024-2025 northern hemisphere influenza season contain the following:

Egg-based vaccines

- an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
- an A/Thailand/8/2022 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture- or recombinant-based vaccines

- an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
- an A/Massachusetts/18/2022 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2024-2025 northern hemisphere influenza season: While the B/Yamagata lineage vaccine component should be excluded as it is no longer warranted, where quadrivalent vaccines are still in use, the B/Yamagata lineage component remains unchanged:

Egg-, cell- or recombinant-based Vaccines

- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

引用元：WHO ウェブサイト

<https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season>

Influenza A(H1N1)pdm09 egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2024-2025 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

23 February 2024

Candidate vaccine viruses (CVVs) antigenically like A/Victoria/4897/2022 (egg-derived) - Accession number (GISAID): EPI_ISL_16714268

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Victoria/4897/2022	Wild type virus			WHO CCs MHRA, UK
	IVR-238	Classical	Seqirus	CCDC, China MHRA, UK VIDRL, Australia NIID, Japan
A/West Virginia/30/2022	Wild type virus			CDC, USA MHRA, UK
	IVR-239	Classical	Seqirus	VIDRL, Australia NIID, Japan
	X-393		NYMC	NYMC, USA MHRA, UK
	X-393A			NYMC, USA MHRA, UK
A/Wisconsin/67/2022	Wild type virus			CDC, USA MHRA, UK
	X-397	Classical	NYMC	CDC, USA
A/Norway/31694/2022	Wild type virus			FCI, UK MHRA, UK
	NIB-133	Classical	MHRA	MHRA, UK
A/Catalonia/NSVH161512065/2022	Wild type virus			FCI, UK
	NIB-134	Classical	MHRA	MHRA, UK
A/Sichuan-Qingyang/SWL1148/2023	Wild type virus			WHO CCs
	CNIC-2301	Classical	CNIC	CCDC, China MHRA, UK

引用元：WHO ウェブサイト

<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

Influenza A(H3N2) egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2024-2025 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)².

23 February 2024

Candidate vaccine viruses antigenically like A/Thailand/8/2022 (egg-derived) – Accession number (GISAID): EPI_ISL_16014504

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Thailand/8/2022	Wild type virus			WHO CCs
	IVR-237	Classical	Seqirus	VIDRL, Australia NIID, Japan
A/California/122/2022	Wild type virus			CDC, USA MHRA, UK
	SAN-022	Classical	Sanofi	Sanofi, USA NIID, Japan
	CBER-54A	Classical	CBER	CBER/FDA, USA
A/Brisbane/837/2022	Wild type virus			VIDRL, Australia
	IVR-246	Classical	Seqirus	VIDRL, Australia NIID, Japan
A/Brandenburg/15/2022	Wild type virus			FCI, UK MHRA, UK
A/Sichuan-Gaoxin/1144/2023	Wild type virus			WHO CCs MHRA, UK
	CNIC-2302D	Classical	CCDC	WHO CCs MHRA, UK
A/Sichuan-Jianyang/35/2023	Wild type virus			WHO CCs MHRA, UK
	CNIC-2303A	Classical	CCDC	WHO CCs MHRA, UK
	CNIC-2303C			WHO CCs MHRA, UK
A/California/45/2023	Wild type virus			CDC, USA

引用元：WHO ウェブサイト

<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

Influenza B Victoria lineage egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2024-2025 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

23 February 2024

Candidate vaccine viruses (antigenically like B/Austria/1359417/2021 (egg derived) - Accession number (GISAID): EPI_ISL_1519459

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Austria/1359417/2021	Wild type virus			WHO CCs MHRA, UK
	BVR-26	Classical	Seqirus	VIDRL, Australia MHRA, UK NIID, Japan
	BX-107A	Classical	NYMC	CDC, USA MHRA, UK NYMC, USA
B/Michigan/01/2021	Wild type virus			CDC, USA MHRA, UK NIID, Japan
B/Singapore/WUH4618/2021	Wild type virus			WHO CCs MHRA, UK
B/Guangdong-Zhenjiang/1516/2021	Wild type virus			WHO CCs
	CNIC-2107A	Classical	CCDC, China	WHO CCs MHRA, UK
B/Zhejiang-Nanhu/1854/2021	Wild type virus			WHO CCs
	BX-117	Classical	NYMC	NYMC, USA MHRA, UK
B/Zhejiang-Xiacheng/11085/2021	Wild type virus			WHO CCs MHRA, UK
	BX-115	Classical	NYMC	NYMC, USA
B/Shaanxi-Baota/1278/2022	Wild type virus			WHO CCs MHRA, UK
	BX-121	Classical	NYMC	NYMC, USA
	BX-121A			

引用元：WHO ウェブサイト

<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

Influenza B Yamagata lineage egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2024-2025 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

23 February 2024

Candidate vaccine viruses (antigenically like B/Phuket/3073/2013 (egg derived) - Accession number (GISAID): EPI_ISL_168822

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Phuket/3073/2013	Wild type virus			WHO CCs MHRA, UK
	BVR-1B	Classical	Seqirus	VIDRL, Australia
B/California/12/2015	Wild type virus			CDC, USA
	BX-59A	Classical	NYMC	MHRA, UK NYMC, USA
	BX-59B			MHRA, UK NYMC, USA
B/Brisbane/9/2014	Wild type virus			WHO CCs MHRA, UK
B/Utah/09/2014	Wild type virus			CDC, USA MHRA, UK
B/Arizona/10/2015	BX-63	Classical	NYMC	MHRA, UK NYMC, USA
	BX-63A			MHRA, UK NYMC, USA
B/Hong Kong/3417/2014	Wild type virus			NYMC, USA MHRA, UK
	BX-57	Classical	NYMC	MHRA, UK NYMC, USA

引用元：WHO ウェブサイト

<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>